Telemedycyna Polska (WAR:TMP) 5-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:TMP Telemedycyna Polska SA WAR:TMP
31 GF Score
Price zł0.61
GF Value zł0.80
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Telemedycyna Polska 5-Year EBITDA Growth Rate?

Telemedycyna Polska WAR:TMP 31 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates WAR:TMP with a GF Score™ of 31/100 and a GF Value™ of zł0.80 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Telemedycyna Polska's EBITDA per Share for the three months ended in Mar. 2026 was zł0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Telemedycyna Polska was 60.50% per year. The lowest was -66.20% per year. And the median was 7.70% per year.

Telemedycyna Polska  (WAR:TMP) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Telemedycyna Polska 5-Year EBITDA Growth Rate Related Terms

WAR:TMP vs VEEV, BTSG, HQY: 5-Year EBITDA Growth Rate Comparison

For the Health Information Services subindustry, Telemedycyna Polska's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telemedycyna Polska 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Telemedycyna Polska's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Telemedycyna Polska's 5-Year EBITDA Growth Rate falls into.


WAR:TMP
31GF Score
Telemedycyna Polska SA WAR:TMP
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telemedycyna Polska 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Telemedycyna Polska (WAR:TMP) has a 5-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Telemedycyna Polska and its competitors.
Is Telemedycyna Polska's 5-Year EBITDA Growth Rate too high?
Telemedycyna Polska's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Telemedycyna Polska has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telemedycyna Polska's 5-Year EBITDA Growth Rate compare to VEEV and BTSG?
Telemedycyna Polska's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Telemedycyna Polska and its competitors. Telemedycyna Polska's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telemedycyna Polska stock overvalued right now?
Based on GuruFocus' analysis, Telemedycyna Polska (WAR:TMP) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.80, compared to a current price of zł0.61 — trading 23.8% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Telemedycyna Polska's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Telemedycyna Polska (WAR:TMP), the current 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telemedycyna Polska (WAR:TMP) Overvalued in 2026?

Based on GuruFocus' analysis, Telemedycyna Polska stock appears to be undervalued. The current stock price of zł0.61 is trading 23.8% below its estimated GF Value™ of zł0.80. GuruFocus considers Telemedycyna Polska to be Modestly Undervalued.

Key valuation signals for WAR:TMP:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: zł0.80 vs. price of zł0.61 (23.8% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the WAR:TMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telemedycyna Polska Business Description

Address Ulica Ligocka 103, Katowice, POL, 40-568
Telemedycyna Polska SA offers telecardiology services for individual patients and medical facilities in Poland. The company offers cardiologic care services through telephone and Internet. The company also provides telemedical services to health centres.
31GF Score

Get the complete analysis for WAR:TMP

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.61
Price
zł0.80
GF Value